Kimberly Yonkers to Drug Administration Schedule
This is a "connection" page, showing publications Kimberly Yonkers has written about Drug Administration Schedule.
Connection Strength
0.248
-
Yonkers KA, Holthausen GA, Poschman K, Howell HB. Symptom-onset treatment for women with premenstrual dysphoric disorder. J Clin Psychopharmacol. 2006 Apr; 26(2):198-202.
Score: 0.061
-
Yonkers KA, Pearlstein T, Fayyad R, Gillespie JA. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. J Affect Disord. 2005 Apr; 85(3):317-21.
Score: 0.057
-
Pearlstein T, Yonkers KA. Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder. Expert Opin Pharmacother. 2002 Jul; 3(7):979-91.
Score: 0.047
-
Yonkers KA. Antidepressants in the treatment of premenstrual dysphoric disorder. J Clin Psychiatry. 1997; 58 Suppl 14:4-10; discussion 11-3.
Score: 0.032
-
Yonkers KA, Kando JC, Cole JO, Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry. 1992 May; 149(5):587-95.
Score: 0.023
-
Cohen LS, Soares CN, Yonkers KA, Bellew KM, Bridges IM, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom Med. 2004 Sep-Oct; 66(5):707-13.
Score: 0.014
-
Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2002 Dec; 100(6):1219-29.
Score: 0.012